Emerging role of metabolic reprogramming in hyperoxia-associated neonatal diseases.


Journal

Redox biology
ISSN: 2213-2317
Titre abrégé: Redox Biol
Pays: Netherlands
ID NLM: 101605639

Informations de publication

Date de publication:
10 2023
Historique:
received: 07 06 2023
revised: 19 08 2023
accepted: 25 08 2023
medline: 13 9 2023
pubmed: 3 9 2023
entrez: 2 9 2023
Statut: ppublish

Résumé

Oxygen therapy is common during the neonatal period to improve survival, but it can increase the risk of oxygen toxicity. Hyperoxia can damage multiple organs and systems in newborns, commonly causing lung conditions such as bronchopulmonary dysplasia and pulmonary hypertension, as well as damage to other organs, including the brain, gut, and eyes. These conditions are collectively referred to as newborn oxygen radical disease to indicate the multi-system damage caused by hyperoxia. Hyperoxia can also lead to changes in metabolic pathways and the production of abnormal metabolites through a process called metabolic reprogramming. Currently, some studies have analyzed the mechanism of metabolic reprogramming induced by hyperoxia. The focus has been on mitochondrial oxidative stress, mitochondrial dynamics, and multi-organ interactions, such as the lung-gut, lung-brain, and brain-gut axes. In this article, we provide an overview of the major metabolic pathway changes reported in hyperoxia-associated neonatal diseases and explore the potential mechanisms of metabolic reprogramming. Metabolic reprogramming induced by hyperoxia can cause multi-organ metabolic disorders in newborns, including abnormal glucose, lipid, and amino acid metabolism. Moreover, abnormal metabolites may predict the occurrence of disease, suggesting their potential as therapeutic targets. Although the mechanism of metabolic reprogramming caused by hyperoxia requires further elucidation, mitochondria and the gut-lung-brain axis may play a key role in metabolic reprogramming.

Identifiants

pubmed: 37659187
pii: S2213-2317(23)00266-5
doi: 10.1016/j.redox.2023.102865
pmc: PMC10480540
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102865

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there is no conflct of interest.

Auteurs

Tong Sun (T)

Department of Pediatics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Haiyang Yu (H)

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Danni Li (D)

Department of Pediatics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

He Zhang (H)

Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: zhangh5@sj-hospital.org.

Jianhua Fu (J)

Department of Pediatics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: fujh_sj@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH